iCell GABANeurons APP A673T, 01279

Genetic mutations in amyloid precursor protein (APP) have been found to contribute to the early-onset or prevention of Alzheimer’s disease. The A673T variant of APP, identified via genetic screening of Icelandic and Scandinavian populations, is associated with protection against Alzheimer’s disease, age-related cognitive decline, and amyloid pathology. While the mechanisms of action are not completely understood, the A673T mutation is suggested to decrease its affinity to β-secretase, reduced Aβ production, and a decreased frequency of APP A673T aggregation.

iCell GABANeurons APP A673T were developed as a cellular model to investigate protective effects of this APP variant. The homozygous mutation was engineered into apparently healthy normal induced pluripotent stem cells, followed by differentiation into cortical neurons that exhibit a majority GABAergic phenotype.

Additionally, iCell GABANeuron APP A673V cells with the pathogenic APP variant are ideal for studying early-onset Alzheimer’s disease.

Features of iCell GABANeurons APP A673T:

• Fully differentiated: ≥95% pure neuronal population
• Cell population consists primarily of GABAergic (inhibitory) neurons
• Engineered for homozygous A673T mutation.
• Altered neural activity phenotype compared to isogenic control
• Expresses Tau, APP, and amyloid beta isoforms
• Aβ levels can be modulated by drugs treatments
• Consistent lot-to-lot GABA phenotypes and cell viability
• Isogenic iCell GABANeurons, 01279 are available

View all Alzheimer’s disease cell models here.